The review found no eligible studies for this question.
Citrate showed no clear difference in death at 28 days compared with unfractionated heparin (moderate certainty).
Citrate probably leads to higher successful prevention of clotting compared with unfractionated heparin (moderate certainty).
Citrate showed no clear difference in treatment cessation due to adverse events compared with unfractionated heparin (low certainty).
Citrate showed no clear difference in recovery of kidney function compared with unfractionated heparin (low certainty).
Citrate showed no clear difference in thrombocytopenia compared with unfractionated heparin (low certainty).
The review found no eligible studies for this question.
Unfractionated heparin showed no clear difference in major bleeding compared with low molecular weight heparin (low certainty).
It is very uncertain whether unfractionated heparin changes death: unknown time frame compared with low molecular weight heparin (very low certainty).
Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
The review found no eligible studies for this question.
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
Augmentation of current antidepressant (SSRI) with busiprone (20… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI) with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.